Litcius/Paper detail

Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

Fabio Conforti, Paolo Andrea Zucali, Laura Pala, Chiara Catania, Vincenzo Bagnardi, Isabella Sala, Paolo Della Vigna, Matteo Perrino, Paola Zagami, Chiara Corti, Sara Stucchi, Massimo Barberis, Elena Guerini‐Rocco, Benedetta Di Venosa, Fabio De Vincenzo, Nadia Cordua, Armando Santoro, Giuseppe Giaccone, Tommaso Martino De Pas

2022The Lancet Oncology59 citationsDOI

Topics & Concepts

AxitinibMedicineThymomaInternal medicineThymic carcinomaClinical endpointOncologyProgressive diseaseResponse Evaluation Criteria in Solid TumorsChemotherapySurgeryClinical trialCancerSunitinibMyasthenia Gravis and ThymomaAdrenal and Paraganglionic TumorsVascular Tumors and Angiosarcomas
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial | Litcius